News & Views

  • Integra’s PIPETGIRL still supporting cancer research
    (L-R) Ruth Nieser-Loosli, Corporate Relations Manager, Krebsliga Schweiz; Dr rer. nat. Rolf Marti, Head of Research, Innovation & Development and Member of the Executive Board, Krebsliga Schweiz, Lydiane Saucède, PhD, Product Manager & Application Scientist, Integra Biosciences, Jürg Bass, Marketing Communications Director, Integra Biosciences.

Integra’s PIPETGIRL still supporting cancer research

Jul 17 2019 Read 664 Times

When Integra Biosciences launched the PIPETGIRL in 2015, the company pledged to donate €10 / US$15 from every sale to internationally renowned research institutes dedicated to finding a cure for breast cancer. This limited edition version of the PIPETBOY acu2 pipetting controller is still available today, and the company’s latest donation of 20,000 CHF has been awarded to the Swiss Cancer League (Krebsliga Schweiz).


The Swiss Cancer League is using this money to help fund a project investigating the link between E3 ubiquitin ligases and breast carcinoma. The research, being conducted at ETH Zurich, aims to develop a comprehensive pre-clinical model of hGID E3 ubiquitin ligase function - which is highly over-expressed in up to 55 % of aggressive breast, ovarian and prostate cancers - to help unravel its role in tumour progression and metastasis in breast cancer cells. This model will then be used to develop prognostic markers of cancer progression, and to screen for compounds that may form the basis of a future therapeutic intervention.


Lydiane Saucède, Product Manager and Application Specialist at Integra, commented: “Breast cancer is one of the most common forms of cancer in women globally, and so we are very pleased to once again be helping in the fight against this devastating disease. We are very proud of this initiative, and sales of the PIPETGIRL pipetting controller have now led to over €27,000  (US$ 30,000) in donations to cancer research institutes globally.”

Reader comments

Do you like or dislike what you have read? Why not post a comment to tell others / the manufacturer and our Editor what you think. To leave comments please complete the form below. Providing the content is approved, your comment will be on screen in less than 24 hours. Leaving comments on product information and articles can assist with future editorial and article content. Post questions, thoughts or simply whether you like the content.

Post a Comment

Digital Edition

Lab Asia December 2019

December 2019

In This Edition Mass Spectrometry & Spectroscopy - Translating Proteomic MALDi Tissue Typing to Clinical Pathology - Fusion Protein Complexes Analysed by CG-MALS - Non-equivalent, Multivalen...

View all digital editions


Nepal Lab

Dec 13 2019 Kathmandu, Nepal

SLAS 2020

Jan 25 2020 San Diego, CA, USA

Arab Health

Jan 27 2020 Dubai, UAE

Nano Tech 2020

Jan 29 2020 Tokyo, Japan


Jan 29 2020 Ghent, Belgium

View all events